These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 7507945)

  • 1. Proliferating cell nuclear antigen distribution in keratoacanthoma and squamous cell carcinoma.
    Phillips P; Helm KF
    J Cutan Pathol; 1993 Oct; 20(5):424-8. PubMed ID: 7507945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic neoplasms with squamous phenotype: actinic keratosis, keratoacanthoma and squamous cell carcinoma of the skin.
    Krunic AL; Garrod DR; Madani S; Buchanan MD; Clark RE
    Br J Cancer; 1998 Apr; 77(8):1275-9. PubMed ID: 9579833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keratoacanthoma and squamous cell carcinoma: study of PCNA and Le(Y) expression.
    Tsuji T
    J Cutan Pathol; 1997 Aug; 24(7):409-15. PubMed ID: 9274958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferating cell nuclear antigen (PCNA) expression in pseudoepitheliomatous hyperplasia, keratoacanthoma and squamous cell carcinoma of the skin.
    Li J; Lee YS
    Ann Acad Med Singap; 1996 Jul; 25(4):526-30. PubMed ID: 8893923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferating cell nuclear antigen immunostaining in keratoacanthoma and squamous cell carcinoma of the skin.
    Royds JA; Stephenson TJ; Silcocks PB; Bleehen SS
    Pathologica; 1994 Dec; 86(6):612-6. PubMed ID: 7617390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors.
    Cain CT; Niemann TH; Argenyi ZB
    Am J Dermatopathol; 1995 Aug; 17(4):324-31. PubMed ID: 8600793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cell-cycle proteins p53, p21 (WAF-1), PCNA and Ki-67 in benign, premalignant and malignant skin lesions with implicated HPV involvement.
    Lu S; Tiekso J; Hietanen S; Syrjänen K; Havu VK; Syrjänen S
    Acta Derm Venereol; 1999 Jul; 79(4):268-73. PubMed ID: 10429981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desmoglein in multiple self-healing squamous epithelioma of Ferguson-Smith--comparison of staining patterns with actinic keratoacanthoma and squamous cell carcinoma of the skin.
    Krunic AL; Garrod DR; Hunter JA; Clark RE
    Arch Dermatol Res; 1998 Jun; 290(6):319-24. PubMed ID: 9705163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
    Mukunyadzi P; Sanderson RD; Fan CY; Smoller BR
    Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin.
    Sakiz D; Turkmenoglu TT; Kabukcuoglu F
    Pathol Res Pract; 2009; 205(9):589-94. PubMed ID: 19577853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki-67 may be useful in differentiating between keratoacanthoma and cutaneous squamous cell carcinoma.
    Scola N; Segert HM; Stücker M; Altmeyer P; Gambichler T; Kreuter A
    Clin Exp Dermatol; 2014 Mar; 39(2):216-8. PubMed ID: 24524559
    [No Abstract]   [Full Text] [Related]  

  • 12. Glut-1 expression and in situ CD1a/CD57 immunologic deficit in keratoacanthoma and squamous cell carcinoma of immunocompetent patients.
    Cabibi D; Aragona F; Guarnotta C; Rodolico V; Zerilli M; Belmonte B; Schillaci L; Aragona F
    Appl Immunohistochem Mol Morphol; 2011 May; 19(3):239-45. PubMed ID: 21475039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-catenin and CD44 expression in keratoacanthoma and squamous cell carcinoma of the skin.
    Tataroglu C; Karabacak T; Apa DD
    Tumori; 2007; 93(3):284-9. PubMed ID: 17679465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in sialyl-Tn antigen expression between keratoacanthomas and cutaneous squamous cell carcinomas.
    Jensen P; Clausen OP; Bryne M
    J Cutan Pathol; 1999 Apr; 26(4):183-9. PubMed ID: 10335895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoexpression of Bcl-x in squamous cell carcinoma and keratoacanthoma: differences in pattern and correlation with pathobiology.
    Tan KB; Lee YS
    Histopathology; 2009 Sep; 55(3):338-45. PubMed ID: 19723149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma.
    Kerschmann RL; McCalmont TH; LeBoit PE
    Arch Dermatol; 1994 Feb; 130(2):181-6. PubMed ID: 8304756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical staining of proliferating cell nuclear antigen (PCNA) in malignant and nonmalignant skin diseases.
    Kawahira K
    Arch Dermatol Res; 1999; 291(7-8):413-8. PubMed ID: 10482011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma.
    Vasiljević N; Andersson K; Bjelkenkrantz K; Kjellström C; Månsson H; Nilsson E; Landberg G; Dillner J; Forslund O
    Int J Cancer; 2009 May; 124(10):2361-6. PubMed ID: 19165861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry.
    Biesterfeld S; Josef J
    Anticancer Res; 2002; 22(5):3019-23. PubMed ID: 12530035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCNA expression in cutaneous keratinous neoplasms and verruca vulgaris.
    Penneys NS; Bogaert M; Serfling U; Sisto M
    Am J Pathol; 1992 Jul; 141(1):139-42. PubMed ID: 1352943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.